# A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

Study · id `cardio:ct-nct05785832` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05785832](<https://clinicaltrials.gov/study/NCT05785832>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05785832

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 319 participants.

## Technical summary

Registry record NCT05785832. Randomized; no masking; primary purpose treatment. Start 2023-06-01 (actual); primary completion 2024-09-24 (actual). Results posted on 2025-06-03.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 319 participants (enrolled count; ClinicalTrials.gov record NCT05785832, source copy `cardio:ctgov-nct05785832-2026-05-22`, retrieved 2026-10-26)
- Started: 2023-06-01 (actual) (ClinicalTrials.gov record NCT05785832, source copy `cardio:ctgov-nct05785832-2026-05-22`, retrieved 2026-10-26)
- Primary completion: 2024-09-24 (actual) (ClinicalTrials.gov record NCT05785832, source copy `cardio:ctgov-nct05785832-2026-05-22`, retrieved 2026-10-26)
- Completion: 2024-09-24 (actual) (ClinicalTrials.gov record NCT05785832, source copy `cardio:ctgov-nct05785832-2026-05-22`, retrieved 2026-10-26)
- Results first posted: 2025-06-03 (ClinicalTrials.gov record NCT05785832, source copy `cardio:ctgov-nct05785832-2026-05-22`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT05785832, source copy `cardio:ctgov-nct05785832-2026-05-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05785832-2026-05-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes
- Acronym: 2IQP
- Condition: Type 2 Diabetes Treated With Insulin
- Intervention (Device): t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM
- Intervention (Device): Standard Therapy plus continuous glucose monitoring (CGM)
- Lead sponsor: Tandem Diabetes Care, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Jaeb Center for Health Research
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: Jaeb Center for Health Research (`cardio:org-jaeb-center-for-health-research`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes (`cardio:pubmed-40105270`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level (`cardio:pubmed-40953318`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes (`cardio:pubmed-41264828`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Simplified Meal Bolus Strategies with Control-IQ+ Automated Insulin Delivery Are Safe and Effective in Adults with Type 2 Diabetes (`cardio:pubmed-41264341`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Consistent Benefit of Control-IQ+ Automated Insulin Delivery Across a Range of Characteristics of Adults with Type 2 Diabetes (`cardio:pubmed-41574573`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f8415afac692cd962920bd8944903924c8b639f999fd29fc9e00822a16c987bd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
